Compare Becton Dickinson and Co (BDX) vs Bilibili Inc (BILI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Bilibili Inc — how do they compare? Becton Dickinson and Co trades at $182.09 (market cap $49.41B), while Bilibili Inc trades at $17.45 (market cap $7.65B). The key difference: Becton Dickinson and Co is far larger — about 6.5× Bilibili Inc's market cap, and Becton Dickinson and Co pays a 2.32% dividend while Bilibili Inc pays none. Which is the better fit depends on your goals.
| BDX | BILI | |
|---|---|---|
Market Cap | $49.41B | $7.65B |
Sector | Health | Media |
52-Week High | $185.39 | $35.92 |
52-Week Low | $138.62 | $15.96 |
Enterprise Value | $65.51B | $5.49B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $180.64, up 0.56% today, near its consensus price target of $183. The stock shows bullish technical signals with strong moving averages and recent earnings beats in Q2 2026. Revenue growth is steady, with Q3 2026 reaching $5 billion, though margins face pressure from tariffs. The company maintains a Dividend Aristocrat status with consistent payouts.
Outlook is cautiously optimistic with analyst consensus leaning buy, but risks include margin compression and debt levels. The stock offers stability through dividends and sector resilience, yet investors should monitor earnings sustainability and competitive threats in the medical technology space.
Bilibili (BILI) trades at $17.46, down 8.06% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q1 2026 EPS of $0.19 exceeding expectations. Revenue growth remains steady at 7% year-over-year, with improving margins and a $300 million share repurchase program supporting shareholder value. Analyst sentiment remains overwhelmingly positive with 83% buy ratings.
The investment case balances strong fundamentals against technical weakness. Upside drivers include advertising growth, AI integration, and margin expansion, while risks involve competitive pressures and China's economic environment. With attractive valuation metrics and institutional support, BILI presents a compelling opportunity for patient investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →
